GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Forward PE Ratio

Cadrenal Therapeutics (Cadrenal Therapeutics) Forward PE Ratio : 0.00 (As of Jun. 22, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Forward PE Ratio?

Cadrenal Therapeutics's Forward PE Ratio for today is 0.00.

Cadrenal Therapeutics's PE Ratio without NRI for today is 0.00.

Cadrenal Therapeutics's PE Ratio for today is 0.00.


Cadrenal Therapeutics Forward PE Ratio Historical Data

The historical data trend for Cadrenal Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Forward PE Ratio Chart

Cadrenal Therapeutics Annual Data
Trend
Forward PE Ratio

Cadrenal Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Cadrenal Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Cadrenal Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's Forward PE Ratio falls into.



Cadrenal Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cadrenal Therapeutics  (NAS:CVKD) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cadrenal Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029